Flakozid - drug from the leaves of Phellodendron amurense Rupr., in treatment of diseases of the hepatobiliary system

The aim: to show the effectiveness of the drug Flakozid, which has a broad spectrum of antiviral action in combination with a hepato-protective effect, in the treatment of diseases of the hepatobiliary system. Material and Methods. The analysis of the effectiveness of the drug has been carried out based on the results of clinical studies of Flakozid, presented by Russian clinical institutions. Results. With chronic hepatitis and cirrhosis of the liver, unconjugated hyperbilirubinemia and fatty liver, the use of oral Flakozid in daily doses of 0.3-0.6 g for 25-45 days has led to an improvement in the general condition of patients, reduction of pain in the right hypochondrium, reduction of dyspeptic disorders, reduce the effects of asthenia, increase physical and intellectual performance, improve appetite. Noted a decrease in the level of total bilirubin and the normalization of the level of ALAT, ASAT and alkaline phosphatase. According to cholecystography, the concentration and contractility of the gallbladder improved. In terms of the severity of the therapeutic effect, Flakozid was not inferior to Silibour and Karsil, and in some indicators (improvement in motility of the gallbladder and biliary tract) markedly exceeded them. Conclusions. According to the results of clinical studies, it has been established that treatment of Flakozid has improved the functional state of the liver, reducing the syndrome of cytolysis and cholestasis. Flakozid has recommended in clinical practice in the complex treatment of diseases of the hepatobiliary system, such as CAG, chronic persistent hepatitis, chronic stoneless cholecystitis at the stage of subcompensation and decompensation.

flakozid, chronic hepatitis, chronic stoneless cholecystitis, fatty liver disease